Protection against meningitis arrives in Burkina Faso
For more than a century, meningitis has swept across sub-Saharan Africa on dusty winds with unstoppable force. With each epidemic, the disease decimates communities, killing one in ten people who are sickened and leaving one-quarter of survivors severely debilitated.
On December 6, 2010, people across Burkina Faso, Mali, and Niger began receiving a shot of a new and promising meningitis vaccine. The vaccine was developed specifically to protect from meningococcal A meningitis, the strain of the disease most destructive to people living in Africa’s meningitis belt.
Amid the fanfare of the launch of the new vaccine, schoolchildren in Ouagadougou, Burkina Faso, become the first to be vaccinated with MenAfriVac® vaccine—and to live without fear of epidemic meningitis.
MenAfriVac is a registered trademark of Serum Institute of India Ltd.